A study to evaluate the effects of obesity medications on kidney function in obese patients with chronic kidney disease

A prospective study evaluating changes in urinary albumin before and after pharmacotherapy in obese patients with chronic kidney disease (CKD) - Prospective evaluation of urinary albumin changes by GLP-1/GIP receptor agonists in obese patients with CKD

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061619

Enrollment

Registered

2026-05-18

Start date

2026-02-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity complicated with Chronic Kidney Disease (CKD)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who meet all of the following criteria: 1.Patients diagnosed with obesity who will start treatment with a GLP-1RA or GIP/GLP-1RA based on the physician's judgment. 2.Patients with chronic kidney disease (CKD) (defined as an albuminuric state with a urinary albumin-to-creatinine ratio (UACR) of >= 30 mg/gCr, or an estimated glomerular filtration rate (eGFR) of < 60 mL/min/1.73m2, or both). 3.Age 18 years or older. 4.Individuals who have received an explanation about participating in this study and provided written consent.

Exclusion criteria

Exclusion criteria: Individuals falling under any of the following are excluded: 1.Pregnant or breastfeeding women. 2.Patients deemed inappropriate by the attending physician due to their medical condition, treatment status, or other reasons.

Design outcomes

Primary

Measure	Time frame
Change in urinary albumin-to-creatinine ratio (UACR) from baseline to 52 weeks after the initiation of treatment	—

Secondary

Measure	Time frame
1. Changes in physical indices (body weight, BMI) from baseline to 52 weeks. 2. Changes in renal function indices (eGFR, etc.) from baseline to 52 weeks. 3. Changes in metabolic/organ function indices and blood pressure (HbA1c, total cholesterol, LDL-C, triglycerides, uric acid, AST, ALT, gamma-GTP, blood pressure) from baseline to 52 weeks. 4. Transitions in urinary albumin-to-creatinine ratio (UACR) at baseline, 24 weeks, and 52 weeks after the start of treatment.	—

Measure

Time frame

1. Changes in physical indices (body weight, BMI) from baseline to 52 weeks. 2. Changes in renal function indices (eGFR, etc.) from baseline to 52 weeks. 3. Changes in metabolic/organ function indices and blood pressure (HbA1c, total cholesterol, LDL-C, triglycerides, uric acid, AST, ALT, gamma-GTP, blood pressure) from baseline to 52 weeks. 4. Transitions in urinary albumin-to-creatinine ratio (UACR) at baseline, 24 weeks, and 52 weeks after the start of treatment.

—

Countries

Japan

Contacts

Public ContactEri Harada

Kagawa University Hospital Department of Endocrinology and Metabolism

muraeri0217@gmail.com087-891-2230

Outcome results